CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
- Forums
- ASX - By Stock
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
CATT of course tested ranibizumab (Lucentis) as the control...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
40.8¢ |
Change
0.003(0.62%) |
Mkt cap ! $504.7M |
Open | High | Low | Value | Volume |
41.5¢ | 41.5¢ | 40.0¢ | $233.0K | 571.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 258387 | 40.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.0¢ | 74069 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 269707 | 0.405 |
24 | 468360 | 0.400 |
13 | 258455 | 0.395 |
18 | 424192 | 0.390 |
5 | 141900 | 0.385 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 81939 | 4 |
0.415 | 234516 | 15 |
0.420 | 191336 | 10 |
0.425 | 76749 | 7 |
0.430 | 235350 | 5 |
Last trade - 12.00pm 26/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |